Metabolic control
Synergistic co-feeding balances carbon, ATP, and reducing power.
C1 Foundry is developing a two-stage biological platform that converts CO2 and H2 into acetate and then into lipid and hydrocarbon intermediates for sustainable aviation fuel production.
Two-stage biological architecture
C1 inputs
CO2 + H2
Carbon and reducing equivalents enter the platform.
Stage 1
M. thermoacetica
Converts CO2 and H2 to acetate; controlled glucose co-feeding supports ATP generation.
Stage 2
Y. lipolytica
Converts acetate toward long-chain fatty acids and terpenoid-derived intermediates; gluconate supports reducing power.
Initial commercial handoff
SAF producers / refiners
Receive lipid-rich feedstock or intermediates for downstream upgrading into qualified SAF.
Core innovation
Synergistic co-feeding balances carbon, ATP, and reducing power.
Metabolic engineering targets fatty-acid and terpenoid-derived hydrocarbon structures.
Continuous bioprocessing targets productivity, stability, and eventual industrial scale.
Commercial focus
The initial product is a lipid-rich SAF feedstock or intermediate for SAF producers and refiners—not finished or certified jet fuel. C1 Foundry is concentrating early development on carbon allocation, productivity, titer, yield, energy demand, recovery, and downstream upgrading requirements.
Development boundary
Scientific foundation
Development questions
Commercial pathway
Commercialization
C1 Foundry is seeking technical and customer input on product specifications, process integration, recovery, upgrading, and the performance thresholds that matter to SAF producers and refiners.